These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 12823096

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats.
    Prié S, Leung TK, Cernacek P, Ryan JW, Dupuis J.
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1312-8. PubMed ID: 9316840
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.
    Kosanovic D, Kojonazarov B, Luitel H, Dahal BK, Sydykov A, Cornitescu T, Janssen W, Brandes RP, Davie N, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Schermuly RT.
    Respir Res; 2011 Jun 23; 12(1):87. PubMed ID: 21699729
    [Abstract] [Full Text] [Related]

  • 10. Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension.
    Nishida M, Eshiro K, Okada Y, Takaoka M, Matsumura Y.
    J Cardiovasc Pharmacol; 2004 Aug 23; 44(2):187-91. PubMed ID: 15243299
    [Abstract] [Full Text] [Related]

  • 11. Defective intracellular calcium handling in monocrotaline-induced right ventricular hypertrophy: protective effect of long-term endothelin-A receptor blockade with 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)- 4-oxobut-2-enoate-sodium (PD 155080).
    Brunner F, Wölkart G, Haleen S.
    J Pharmacol Exp Ther; 2002 Feb 23; 300(2):442-9. PubMed ID: 11805203
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. EndothelinA receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension.
    Prié S, Stewart DJ, Dupuis J.
    Circulation; 1998 Jun 02; 97(21):2169-74. PubMed ID: 9626178
    [Abstract] [Full Text] [Related]

  • 14. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
    Schiffrin EL, Turgeon A, Deng LY.
    Br J Pharmacol; 1997 Jul 02; 121(5):935-40. PubMed ID: 9222550
    [Abstract] [Full Text] [Related]

  • 15. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats.
    Cui B, Cheng YS, Dai DZ, Li N, Zhang TT, Dai Y.
    Clin Exp Pharmacol Physiol; 2009 Feb 02; 36(2):169-75. PubMed ID: 18986320
    [Abstract] [Full Text] [Related]

  • 16. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
    Tilton RG, Munsch CL, Sherwood SJ, Chen SJ, Chen YF, Wu C, Block N, Dixon RA, Brock TA.
    Pulm Pharmacol Ther; 2000 Feb 02; 13(2):87-97. PubMed ID: 10799286
    [Abstract] [Full Text] [Related]

  • 17. YM598, an orally active ET(A) receptor antagonist, ameliorates the progression of cardiopulmonary changes and both-side heart failure in rats with cor pulmonale and myocardial infarction.
    Fujimori A, Miyauchi T, Sakai S, Yuyama H, Iemitsu M, Sanagi M, Sudoh K, Goto K, Shikama H, Yamaguchi I.
    J Cardiovasc Pharmacol; 2004 Nov 02; 44 Suppl 1():S354-7. PubMed ID: 15838319
    [Abstract] [Full Text] [Related]

  • 18. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
    Hill NS, Warburton RR, Pietras L, Klinger JR.
    J Appl Physiol (1985); 1997 Oct 02; 83(4):1209-15. PubMed ID: 9338430
    [Abstract] [Full Text] [Related]

  • 19. Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels.
    Sauvageau S, Thorin E, Villeneuve L, Dupuis J.
    Pulm Pharmacol Ther; 2009 Aug 02; 22(4):311-7. PubMed ID: 19489130
    [Abstract] [Full Text] [Related]

  • 20. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS, Kim DH, Lee YJ, Lee SE, Kang WJ, Chang HJ, Shin JS.
    Respir Res; 2014 Nov 25; 15():148. PubMed ID: 25420924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.